共 230 条
[1]
Davies C(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[2]
Pan H(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784
[3]
Godwin J(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816
[4]
Gray R(2014)Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update J Clin Oncol 32 2255-2269
[5]
Arriagada R(2005)CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30-39
[6]
Burstein HJ(2004)Pharmacological characterization of 4-hydroxy- Breast Cancer Res Treat 85 151-159
[7]
Temin S(2005)-desmethyl tamoxifen, a novel active metabolite of tamoxifen Cancer Chemother Pharmacol 55 471-478
[8]
Anderson H(2003)Endoxifen (4-hydroxy- J Natl Cancer Inst 95 1758-1764
[9]
Buchholz TA(2008)-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Expert Rev Mol Med 10 e34-132
[10]
Davidson NE(2010)Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine BMJ 340 c693-61